$SYRE

$99.05 +$0.00 (0.0%) After hours

$SYRE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 88.2M shares outstanding

Who owns SYRE?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 77.2%

FMR LLC 14.8% · Harwin Peter Evan 11.6%

Institutional ownership

100.0%

+6.2 pts vs last qtr

Institutional holders

263

+65 vs last qtr

Net shares bought

+13.1M

by institutions in Q2 2026

New / sold out

91 / 26

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +2.2M
Paradigm Biocapital Advisors LP +1.9M

Biggest sellers in Q2 2026

Fairmount Funds Management LLC SOLD OUT −4.0M
Janus Henderson Group PLC SOLD OUT −1.7M

Who is planning to sell?

Notices of proposed sale, last 12 months

$443M

17 notices from 6 people

Shares covered

5.3M

6.02% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Fairmount Healthcare Fund II L.P. Director $400M
Cameron Turtle Director 10b5-1 $12.8M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2021–FY2023

+162.3%

+61.95% a year

Each share's claim on the business

−61.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $40.8M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years84% Under 1 year16%

Quarterly turnover

24.3%

of institutional shares changed hands

Top 10 managers, median time held

2.5 years

Super Investors

Investment managers reporting SYRE on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	13.0M	14.77%	+1.2M (+10.6%)	2023	0.1%
Shares held by quarter Peak holding13.0M (Q2'26) Change over 8 quarters+5.4M Share of the company14.770% FMR LLC's full portfolio →
B BlackRock, Inc.	6.5M	7.38%	+985.4K (+17.8%)	2023	0.0%
Shares held by quarter Peak holding6.5M (Q2'26) Change over 8 quarters+3.8M Share of the company7.380% BlackRock, Inc.'s full portfolio →

FMR LLC

13.0M

% of company

14.77%

Change vs last qtr

+1.2M (+10.6%)

Held since

2023

BlackRock, Inc.

6.5M

% of company

7.38%

Change vs last qtr

+985.4K (+17.8%)

Held since

2023

28 more super investors behind a free account

See every manager holding Spyre Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting SYRE on Form N-PORT; together they hold 38.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
SW SMALLCAP World Fund Inc SMALLCAP World Fund Inc	$247M	2.8M	3.15%	0.26%	June 30, 2026
FG Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust	$247M	2.8M	3.13%	0.25%	August 31, 2026

SMALLCAP World Fund Inc

Position value

$247M

% of company

3.15%

% of the fund

0.26%

As of

June 30, 2026

Fidelity Growth Company Fund

Fidelity Mt. Vernon Street Trust

Position value

$247M

% of company

3.13%

% of the fund

0.25%

As of

August 31, 2026

23 more funds behind a free account

See every fund holding Spyre Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
HP Harwin Peter Evan 5%+ holder 13D · 10.0%	10.2M	11.55%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company11.550% Disclosed stake13D · 10.0% View the 13D/G filing →
KT Kiselak Tomas 5%+ holder 13D · 10.0%	10.2M	11.55%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company11.550% Disclosed stake13D · 10.0% View the 13D/G filing →

Harwin Peter Evan

5%+ holder13D · 10.0%

10.2M

% of company

11.55%

Change vs last qtr

—

Held since

—

Kiselak Tomas

5%+ holder13D · 10.0%

10.2M

% of company

11.55%

Change vs last qtr

—

Held since

—

6 more holders behind a free account

See every insider and 5%+ holder of Spyre Therapeutics Inc.

Comments